대한뉴팜

Daehan New Pharm Officially Launches Redesigned Korean and English Company Website (www.dhnp.co.kr) in 2005 The newly revamped website maximizes visual promotional impact with elegant design while providing more detailed content about the company overall. It offers sector-specific health information for visitors, convenient product search features by business unit, an online application system for job applicants to build a talent pool, and an online purchasing system for partners, delivering diverse functionalities. Unique to Daehan New Pharm compared to typical pharmaceutical websites, an internal online café was introduced to activate staff clubs and enhance employee communication. The company has continuously supported employee clubs to promote a healthy corporate culture, and this new online café is expected to foster exchange between HQ and factory staff and contribute to developing a more progressive corporate culture. Additionally, Daehan New Pharm established a semi-SFA (Sales Force Automation) system integrating sales management and sales information sharing. This system allows sales staff to manage their basic sales activities directly online, while managers and executives can simultaneously monitor consolidated information to make decisions, creating a novel concept of an internal intranet. Daehan New Pharm's semi-SFA system achieves low cost and high efficiency in sales management with essential sales management modules tailored for individual sales staff, enabling easier adaptation than traditional complex systems used by other pharmaceutical companies. The remarkable aspect of this website redevelopment is the integration and operation of three online systems. Through this revamp, Daehan New Pharm aims to strengthen proactive online promotion and departmental online businesses, enhance sales capabilities, and realize organizational harmony, actively responding to pharmaceutical market changes for continuous growth. Meanwhile, since 2003, Daehan New Pharm has also operated a marketing website for obesity-related products called Diet Pharm (www.dietpharm.co.kr).

Daehan New Pharm Strengthens Specialization in Obesity Treatment Field Daehan New Pharm Co., Ltd. (CEO Park Myung-rae) kicked off 2005 with the launch of new products including Fastin Tablet for obesity treatment and iCool Capsules for eye nutrition. At the New Year ceremony held at the Suwon Lavidol Resort with all employees in attendance, the company committed to achieving its sales goals for the year and making 2005 a year of corporate growth. Fastin Tablet contain phentermine hydrochloride, a drug approved by the US FDA for appetite suppression in patients with exogenous obesity. Daehan New Pharm has actively marketed a diverse portfolio of products in the fields of appetite suppressants, fat absorption inhibitors, thermogenesis promoters, and obesity treatment mesotherapy formulations. The launch of Fastin Tablet, expected to capture a significant market, is aimed at cementing the company’s position as a specialist pharmaceutical company in obesity treatment. The obesity treatment market was valued at approximately 50 billion KRW in 2004, and Daehan New Pharm anticipates capturing at least 15% of this market. Recognizing that many clinics show great interest in treating obesity patients but lack familiarity with patient engagement methods, the company plans to train obesity specialist coordinators and develop customer-centric marketing strategies.

Daehan New Pharm Co., Ltd. (CEO Park Myung-rae) has newly launched 'Spo-K Plaster,' an arthritis and muscle pain treatment containing menthol, thereby entering the patch market. Each patch contains 30 mg of ketoprofen and features an added L-menthol component, providing a cooling sensation immediately upon application. Spo-K uses a non-irritating breathable nonwoven fabric, making it safe for patients with sensitive skin, and its enhanced adhesive technology ensures it adheres well to curved areas such as the knees and elbows. The innovative adhesive technology improves adhesion and significantly reduces the problem of edges curling, common in conventional products. Utilizing advanced Transdermal Drug Delivery System (TDDS) technology, the product targets pain areas directly, avoiding systemic side effects like liver toxicity and gastrointestinal disorders associated with oral administration. The current anti-inflammatory and analgesic patch market is dominated by Ketotop Plaster from Taepyeongyang Pharmaceutical and Kephentek Plaster from Jeil Pharmaceutical, forming approximately a 45 billion KRW market in 2005. Daehan New Pharm's new entry with Spo-K Plaster is expected to actively seek expansion in this market. Through this launch, Daehan New Pharm aims to revitalize the stagnating OTC market with diverse marketing strategies, enhance consumer recognition, and strengthen pharmacy sales. The company plans to balance herbal medicines and Western OTC products as part of their product strategy, using this opportunity as a springboard for invigorating pharmacy operations.

Daehan New Pharm Co., Ltd. (CEO Park Myung-rae) held a celebration ceremony at its headquarters auditorium on October 19, marking its 20th anniversary. The event was attended by employees and executives who reaffirmed their commitment to transforming into a total healthcare group. The ceremony featured introductions to the company’s history, awards for long-term employees and outstanding workers, a ceremonial rice cake cutting, and commemorative speeches. Chairman Lee Wan-jin expressed gratitude to all partner companies and customers who have supported Daehan New Pharm with mutual trust and emphasized the importance of understanding the essence of the pharmaceutical industry to sustain the company’s longevity. He urged management to focus on nurturing talent and fulfilling the company’s role in contributing to the advancement of public health. Founded in 1984, Daehan New Pharm began with the production of veterinary medicines and has since expanded to establish state-of-the-art manufacturing facilities in the Hyangnam pharmaceutical complex. The company has built large-scale production lines for various pharmaceutical formulations, including traditional Korean herbal granules, as well as facilities and business units for health foods, beverages, and baby products, steadily progressing toward becoming a total healthcare group. During the ceremony, long-term service awards for 10 years of dedicated service were presented to Assistant Manager Lim Hee-taek and Assistant Manager Kim Seung-hwan from the veterinary production department.

Daehan New Pharm (CEO Park Myung-rae) held the “2004 Mountain March Competition” on the 4th to establish a sense of purpose and strengthen the sales organization. The event took place on a 60km mountain march course from Yanggu, Gangwon Province, to Inje and Hyeon-ri, with about 130 participants from the sales and sales support departments, including CEO Park. The march, which started at midnight after a sales meeting on the 3rd, was conducted along National Road 31, crossing the now-closed old Gwangchiryung Pass to reach Inje and Hyeon-ri. This route, known as the “hell march course,” typically takes about 15 hours and is known to be challenging even for frontline soldiers. The march was organized by small sales teams that encouraged and pushed each other, and all participants completed the march without anyoneping out in about 15 hours. Notably, three female employees voluntarily participated and completed the march alongside their male colleagues. Participant Lee Chae-il (36), team leader of the Ulsan team, said, “Remembering the spirit of my military service 10 years ago, I reflected on my somewhat lax attitude so far and had a good experience strengthening camaraderie with colleagues who sweat together in the sales field. Based on this spirit and organizational strength, I will do my best to achieve the given targets." Since its listing on KOSDAQ, Daehan New Pharm has been solidifying its sales foundation through sound growth, securing excellent talents, and intensive training. The company plans to continue developing similar mental education programs to maintain organizational strength.

Daehan New Pharm obtained the license for 'Health Functional Food Specialized Manufacturing Business' on August 23, 2004.

Daehan New Pharm (CEO Park Myung-rae) has launched a new liver disease treatment called "Eldamin Soft Capsules," which contains silymarin along with a complex of B vitamins. Silymarin, extracted from Carduus marianus, has been traditionally used as a folk remedy for liver diseases and is known for its excellent effects in protecting the liver from damage, promoting liver cell regeneration, and aiding liver detoxification. The capsules also include six types of B vitamins (B1, B2, B3, B5, B6, B12) that are formulated to support liver function recovery, alleviate fatigue, and help prevent various adult diseases common in modern life. Daehan New Pharm aims to boost pharmacy sales by complementing its existing herbal natural drug lineup and Western OTC products with this new release. The premium packaging sets the consumer price at about 60,000 to 80,000 KRW per bottle (300 capsules), which is expected to contribute to sales at the pharmacy level.

Daehan New Pharm (CEO Park Myung-rae) held the ‘A+ 2004! Management Strategy Seminar and Mountaineering Competition’ over two days on the 2nd and 3rd, aimed at establishing a sense of purpose and revitalizing sales activities. The event took place at Lake Hills Hotel in Songnisan, with about 170 participants including all employees from sales and administrative departments, excluding production site staff. On the first day, participants completed a circuit around Moonjangdae and Sinsendae in Songnisan within about seven hours, with noouts. This was followed by a night of unity, reinforcing the strength of an organized team. The next day’s management strategy seminar involved in-depth discussions on strategies for achieving second-half and full-year 2004 goals, and included the ‘A+ 2004! Management Strategy Declaration Ceremony.’ An awards ceremony for outstanding employees of the first half was also held, where winners received overseas training opportunities in Southeast Asia. Special guest Lee Hee-goo, chairman of Geo Young and former head of the Wholesale Association, delivered a keynote lecture on ‘Salesperson Strategies and Attitudes amid the Pharmaceutical Industry’s Development.’ Chairman Lee encouraged participants to take pride and responsibility in their roles as contributors to public health, despite the many changes and challenges in the domestic pharmaceutical industry environment. Lee Sang-pil, branch manager of Gwangju who received an award for outstanding employee, expressed that the seminar was a meaningful opportunity to reflect on himself and feel limitless possibilities and pride in the company. Since listing on KOSDAQ, Daehan New Pharm has been achieving substantial growth based on the successful establishment of specialty and herbal medicine markets.

Daehan New Pharm (CEO Park Myung-rae) held the 2004 Goal Achievement Rally on March 9th and 10th at the Korea Human Resources Development Institute in Giheung, Gyeonggi Province. Around 150 employees from sales-related departments attended the event, where the first-quarter results were analyzed and plans for achieving the annual goals were reviewed. CEO Park urged all employees to actively respond to changes and to do their best to achieve the goals for the company to advance as a leading, prosperous enterprise. The rally included presentations and evaluations of first-quarter performance and plans for the second to fourth quarters by the Pharmaceutical Business Division, Herbal Medicine Business Division, Animal Medicine Business Division, Bio Business Division, and Overseas Business Division. Unlike previous monthly sales meetings held separately by each division, this event brought together all five divisions along with its affiliate Avent Korea for joint participation. The event also featured discussions on methods for achieving targets by product and client, strategies for recovering bad debts, and detailed action plans formulated through breakout sessions.